1. Home
  2. CALC vs INTS Comparison

CALC vs INTS Comparison

Compare CALC & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • INTS
  • Stock Information
  • Founded
  • CALC 2011
  • INTS 2012
  • Country
  • CALC United States
  • INTS United States
  • Employees
  • CALC N/A
  • INTS N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CALC Health Care
  • INTS Health Care
  • Exchange
  • CALC Nasdaq
  • INTS Nasdaq
  • Market Cap
  • CALC 36.0M
  • INTS 33.4M
  • IPO Year
  • CALC N/A
  • INTS 2023
  • Fundamental
  • Price
  • CALC $2.61
  • INTS $2.20
  • Analyst Decision
  • CALC Strong Buy
  • INTS Strong Buy
  • Analyst Count
  • CALC 5
  • INTS 3
  • Target Price
  • CALC $18.20
  • INTS $8.50
  • AVG Volume (30 Days)
  • CALC 31.0K
  • INTS 41.6K
  • Earning Date
  • CALC 03-27-2025
  • INTS 03-13-2025
  • Dividend Yield
  • CALC N/A
  • INTS N/A
  • EPS Growth
  • CALC N/A
  • INTS N/A
  • EPS
  • CALC N/A
  • INTS N/A
  • Revenue
  • CALC N/A
  • INTS N/A
  • Revenue This Year
  • CALC N/A
  • INTS N/A
  • Revenue Next Year
  • CALC N/A
  • INTS N/A
  • P/E Ratio
  • CALC N/A
  • INTS N/A
  • Revenue Growth
  • CALC N/A
  • INTS N/A
  • 52 Week Low
  • CALC $2.05
  • INTS $1.50
  • 52 Week High
  • CALC $6.27
  • INTS $5.94
  • Technical
  • Relative Strength Index (RSI)
  • CALC 43.94
  • INTS 54.20
  • Support Level
  • CALC $2.32
  • INTS $2.00
  • Resistance Level
  • CALC $3.05
  • INTS $2.37
  • Average True Range (ATR)
  • CALC 0.27
  • INTS 0.31
  • MACD
  • CALC -0.01
  • INTS -0.00
  • Stochastic Oscillator
  • CALC 43.29
  • INTS 48.24

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Share on Social Networks: